Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach

Trial Profile

Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2018

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Ankylosing spondylitis; Autoimmune hepatitis; Behcet's syndrome; Cholangitis; Crohn's disease; Idiopathic thrombocytopenic purpura; Psoriasis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma; Takayasu syndrome; Ulcerative colitis; Wegener's granulomatosis
  • Focus Therapeutic Use
  • Acronyms TRANSREG
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Aug 2018 Planned End Date changed from 13 Feb 2020 to 6 Aug 2021.
    • 17 Aug 2018 Planned primary completion date changed from 14 Jul 2018 to 13 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top